Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.

Mol Cancer Ther · 2026 · PMC13324342 · PMID 41789558

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

A positive trend but no significant correlation was observed between HER2 expression and combination benefit measured by HSA ( R = 0.059; Fig. 4C ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.